| ISSN |
1007-9327 (print) and 2219-2840 (online) |
| Open Access |
This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/Licenses/by-nc/4.0/ |
| Copyright |
© The Author(s) 2026. Published by Baishideng Publishing Group Inc. All rights reserved. |
| Article Reprints |
For details, please visit: http://www.wjgnet.com/bpg/gerinfo/247
|
| Permissions |
For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
|
| Publisher |
Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA |
| Website |
http://www.wjgnet.com |
| Category |
Gastroenterology & Hepatology |
| Manuscript Type |
Retrospective Study |
| Article Title |
Progression after endoscopic treatment for type I gastric neuroendocrine tumors: A single-center retrospective study
|
| Manuscript Source |
Unsolicited Manuscript |
| All Author List |
Ze-Liang Yang, Hui-Ke Wang, Yong Liu, Li-Zhou Dou, Yue-Ming Zhang, Hoi-Ioi Ng, Shun He, Yihe-Bali Chi and Gui-Qi Wang |
| ORCID |
|
| Funding Agency and Grant Number |
| Funding Agency |
Grant Number |
| CAMS Innovation Fund for Medical Sciences |
2021-I2M-1-061, 2021-I2M-1-013, 2021-1-I2M-015 |
|
| Corresponding Author |
Gui-Qi Wang, Academic Fellow, MD, PhD, Professor, Department of Endoscopy, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, No. 17 Panjiayuan Nanli, Chaoyang District, Beijing 100021, China. wangguiq@126.com |
| Key Words |
Type I gastric neuroendocrine tumors; Endoscopic treatment; Neutrophil-to-lymphocyte ratio; Prognosis; Somatostatin analogues |
| Core Tip |
Endoscopic treatment is the standard therapy for type I gastric neuroendocrine tumors, but it may not address underlying disease mechanisms. In this retrospective study of 128 patients, 41 experienced progression. Multivariate Cox regression identified adjuvant somatostatin analog use as a protective factor (hazard ratio = 0.38, 95% confidence interval: 0.17-0.90, P = 0.027) and neutrophil-to-lymphocyte ratio ≥ 2 as a risk factor (hazard ratio = 2.14, 95% confidence interval: 1.08-4.26, P = 0.030). Kaplan-Meier analysis confirmed both as independent prognostic variables. These findings suggest that combining endoscopic therapy with somatostatin analogues improves outcomes. Neutrophil-to-lymphocyte ratio may serve as a simple marker to guide risk stratification. |
| Publish Date |
2026-02-11 07:19 |
| Citation |
Yang ZL, Wang HK, Liu Y, Dou LZ, Zhang YM, Ng HI, He S, Chi YB, Wang GQ. Progression after endoscopic treatment for type I gastric neuroendocrine tumors: A single-center retrospective study. World J Gastroenterol 2026; 32(8): 114268 |
| URL |
https://www.wjgnet.com/1007-9327/full/v32/i8/114268.htm |
| DOI |
https://dx.doi.org/10.3748/wjg.v32.i8.114268 |
